1 November 2018, Wellcome Collection, London


Longevity is “the biggest money fountain that I have ever seen”.
– Billionaire investor Jim Mellon

We are on the verge of a lifespan revolution. In the next 30 years, life expectancy is going to rise to between 110 and 120.

The nascent but rapidly growing longevity industry has the capacity to change forever how we live, and how (and when) we die. Crucially, it will also influence how we successfully invest for the future.

How can we as investors prosper in this new era of longevity?

Our one-day masterclass, Investing in the age of longevity, offers you the rare chance to be involved (and invested) in the birth of a new industry – arguably the greatest investment opportunity of all time.


Selecting the right investments is key and knowledge is fundamental. Investing in the age of longevity will show you how.

Get the inside track on the latest ageing related discoveries

Network with some of the leading longevity scientists and investors

Meet the businesses identified by Jim Mellon as being good investments

Start profiting from the rapid technology evolution.


1 November 2018
09:30 – 17:00

The day-long masterclass will focus on the most recent and meaningful developments in the field of longevity:

  • The longevity landscape
  • Investment strategies – what to look for
  • The science behind the investment
  • Portfolio approach to longevity investing


  • Presentations by companies identified as providing good investment opportunities
  • Panel discussions with both longevity businesses and pre-eminent scientists
  • Ample networking opportunities with company representatives and leading experts on longevity



Jim Mellon

Jim is an entrepreneur with a flair for identifying emerging global trends enabling him to build a worldwide business empire. He is amongst the top 10% in the “Sunday Times Rich List” (Britain’s equivalent to the Forbes list).

He is often described as the British Warren Buffett and he predicted the Credit Crunch of 2007-08 in a book entitled “Wake Up! Survive and Prosper in the Coming Economic Turmoil”. Jim followed this with “The Top 10 Investments for the Next 10 Years” (2008) and subsequently “Cracking the Code” (2012), “Fast Forward” (2014) and, most recently, “Juvenescence” (2017). His monthly “Mellon on the Markets” column in Master Investor Magazine has gained him cult status among investors.

He holds a master’s degree in Politics, Philosophy and Economics from Oxford University. He is on the Board of Trustees of the Buck Institute in California, a trustee of the Biogerontology Institute, and a Fellow of Oriel College, Oxford.

Dr. Aubrey de Grey

Dr. Aubrey de Grey is a biomedical gerontologist based in Mountain View, California, USA, and is the Chief Science Officer of SENS Research Foundation, a California-based 501(c)(3) biomedical research charity that performs and funds laboratory research dedicated to combating the aging process. He is also VP of New Technology Discovery at AgeX Therapeutics, a biotechnology startup developing new therapies in the field of biomedical gerontology. In addition, he is Editor-in-Chief of Rejuvenation Research, the world’s highest-impact peer-reviewed journal focused on intervention in aging. 

He received his BA in computer science and Ph.D. in biology from the University of Cambridge. His research interests encompass the characterisation of all the types of self-inflicted cellular and molecular damage that constitute mammalian aging and the design of interventions to repair and/or obviate that damage.

Dr. de Grey is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organisations. He is a highly sought-after speaker who gives 40-50 invited talks per year at scientific conferences, universities, companies in areas ranging from pharma to life insurance, and to the public.

Jennifer Donohue

Insurance, reinsurance and financial services specialist.

Michael West

Michael D. West, Ph.D. is the founding CEO of AgeX Therapeutics, a biotechnology company focused on the development and commercialisation of novel therapeutics targeting human ageing, and a subsidiary of BioTime, Inc. (NYSE US: BTX), where he also serves as Co-CEO, having joined as CEO in 2007. Prior to BioTime he served in a variety of roles including Chairman, CEO and CSO at Advanced Cell Technology, which, as Ocata Therapeutics, was acquired by Astellas Pharma of Japan in 2016 for $379 Million.

In 1990 Dr. West founded Geron (Geronology) Corp (Nasdaq: GERN) with backing from Kleiner, Perkins, Caufield & Byers and Venrock. For its scientific team he recruited Drs. Elizabeth Blackburn, Carol Greider and Jack Szostak, who collectively went on to win the Nobel Prize in Medicine. While at Geron he also created the research consortium with Prof. James Thomson that led to the first isolation of human embryonic stem cells.

Dr. West received a B.S. Degree from Rensselaer Polytechnic Institute in 1976, an M.S. in Biology from Andrews University in 1982, and a Ph.D. with a concentration on the biology of cellular aging from Baylor College of Medicine in 1989. The author of numerous articles in peer-reviewed scientific journals, he wrote The Immortal Cell: One Scientist’s Quest to Solve the Mystery of Human Aging (DoubleDay, 2003). He has appeared as a guest on NBC’s “Meet the Press” and has testified before the US Congress about the potential lifesaving benefits of regenerative medicine.

Alex Zhavoronkov Ph.D.

CEO of Insilico Medicine, director of the Biogerontology Research Foundation and founder of the International Ageing Research Portfolio.

Mike Kope

CEO of the SENS Research Foundation.



Wellcome Collection
183 Euston Road


Standard ticket: 300 GBP

Tickets are strictly limited and available on a first-come, first-served basis.


Get real investment insights from some of the best minds in the business - with our free Master Investor Magazine.